Certificate of Analysis and Sample Requirements

1. Key takeaways

The Myanmar registration dossier requires a certificate of analysis for the product sample (Certificate of Analysis, COA), serving as supporting evidence of quality conformity. Together with the manufacturing licence, the GMP certificate and the ISO certificate, the COA forms the quality evidence group of the dossier.

GRZAN note: what the COA certifies is the sample batch, not the product model itself. The key to a strong COA is therefore batch traceability — the batch number of the tested sample must connect to the batch record system of the products later placed on sale. The COA essentials can be remembered as 1 core field (the batch number), 2 consistency checks and 1 set of issuance records to be retained.

• Core field — the batch number on the COA;
• Consistency check 1 — COA dates against the labelled production date and shelf life;
• Consistency check 2 — COA batch against the commercial batch records;
• Retained evidence — the COA’s original issuance records.

The traceability obligation extends beyond the dossier itself: import documents such as the invoice, the packing list and the batch numbers must be consistent with the registration certificate information. In other words, the batch discipline that starts with the COA continues through customs clearance and into the market, which is why the batch numbering rules set up for registration should be the same rules the supply chain lives by afterwards.

2. Legal basis

The document requirement, its role as quality evidence and the surrounding obligations it must stay consistent with are summarised below. The COA does not stand alone: its probative value depends on the quality system behind it and on the label and import records it must match. Under the ISO 13485 quality management system, the production and issuance records supporting the certificate are maintained and controlled, which is precisely what makes the certificate verifiable on request.

3. Expert insights

Insight 1: the COA certifies a different object from the other quality documents. The manufacturing licence certifies the entity’s qualification, the ISO certificate certifies the system, and the COA certifies the test results of a specific batch. The three together form a complete chain of quality evidence: entity, system and product. A dossier carrying only one or two of these links asks the reviewer to take the remaining link on trust.

Insight 2: the batch number is the core field of the COA. A COA with a missing batch number, or one whose batch cannot be traced, has its probative force weakened. The batch number is what anchors the analytical result to a physical production event; without it, the certificate describes no identifiable product and the reviewer cannot verify anything about it. Batch numbering rules should therefore be treated as part of the registration infrastructure, not as a manufacturing detail.

Insight 3: the COA must corroborate the production date and shelf life stated on the label. If the dates of the COA batch contradict the label statement, a clarification request follows. The label artwork must in any case carry the warning information, the production date, the shelf life and the manufacturer information, so the COA dates and the label dates are read side by side by design. Aligning them before submission is one of the cheapest consistency wins available.

Insight 4: the counterfeit consumables problem has strengthened the authenticity review of the COA. The Myanmar FDA has intensified its substantive document review in response to counterfeit medical consumables, and the verifiability of the COA matters more than it used to. A certificate that can be checked against the manufacturer’s own issuance records survives this scrutiny; one that cannot does not. Retaining those records is thus no longer an archival nicety but a defensive measure.

Insight 5: the update frequency of the COA must match the production rhythm. At renewal or change, the submitted COA should reflect the current production state. A certificate attached to a batch produced years earlier tells the reviewer nothing about the product being offered today, and its evidentiary value decays with every intervening production change. Linking COA refreshment to the renewal calendar keeps the evidence chain alive.

4. Practical recommendations

• Ensure the COA contains complete batch number information. Establish batch numbering rules that make every certificate traceable.
• Connect the COA batch to the commercial batch record system. Achieve forward and backward traceability.
• Check the consistency of the COA with the label dates. Complete the comparison before submission.
• Retain the original issuance records of the COA. Be ready for authenticity checks.
• Refresh the COA before renewals and changes. It must reflect the current production state.

A convenient way to operationalise all five recommendations is a single COA page in the registration register: the batch number, the production date, the tested shelf-life point, the label dates, the location of the issuance record and the next scheduled refresh, all on one line per certificate. With that page maintained, every question a reviewer or auditor asks about the COA has a one-glance answer, and the quality evidence group stays intact across the certificate’s whole life cycle.

5. Verification checklist

• □ Certificate of analysis for the product sample (COA) obtained
• □ COA confirmed to contain a complete batch number
• □ Traceability between COA batches and commercial records established
• □ Consistency of the COA with the label dates checked
• □ Original issuance records of the COA retained
• □ Linkage mechanism between COA updates and renewals or changes established
• □ COA file included in the registration register management

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including Myanmar. Our team prepares the technical dossier to ASEAN CSDT structure, manages submission and deficiency responses with the Myanmar FDA, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com